Order Article Reprints

Macedo TR, de Queiroz GF, Casagrande TAC, Alexandre PA, Brandão PE, Fukumasu H, Melo SR, Dagli MLZ, Pinto ACBCF, Matera JM. Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone. Cells. 2022; 11(3):571. https://doi.org/10.3390/cells11030571

Macedo, Thais Rodrigues, Genilson Fernandes de Queiroz, Thaís Andrade Costa Casagrande, Pâmela Almeida Alexandre, Paulo Eduardo Brandão, Heidge Fukumasu, Samanta Rios Melo, Maria Lucia Zaidan Dagli, Ana Carolina B. C. Fonseca Pinto, and Julia Maria Matera. 2022. "Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone" Cells 11, no. 3: 571. https://doi.org/10.3390/cells11030571

Macedo, T. R., de Queiroz, G. F., Casagrande, T. A. C., Alexandre, P. A., Brandão, P. E., Fukumasu, H., Melo, S. R., Dagli, M. L. Z., Pinto, A. C. B. C. F., & Matera, J. M. (2022). Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone. Cells, 11(3), 571. https://doi.org/10.3390/cells11030571